Skip to main content
Fumito Ito, MD, General Surgery, Los Angeles, CA, Keck Hospital of USC

FumitoItoMDPhD, FACS

General Surgery • Los Angeles, CA

Breast, Melanoma, Surgical Oncology (Other than Breast)

Surgical Oncologist, University of Southern California, Co-Leader of the Translational and Clinical Sciences Research (TACS) Program and Director of the Flow Cytometry and Immune Monitoring Core, Norris Comprehensive Cancer Center

Join to view full profile

Dr. Ito is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ito's full profile

Already have an account?

Clinical Expertise

  • Breast cancer, Breast surgery, Tumor immunotherapy, Sarcomas, Melanoma and cutaneous malignancies, Cancer Vaccines

Education & Training

  • Strong Memorial Hospital of the University of Rochester
    Strong Memorial Hospital of the University of RochesterFellowship, Complex General Surgical Oncology, 2008 - 2010
  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Surgery, 2005 - 2008
  • University of Washington
    University of WashingtonResidency, Surgery, 2003 - 2005
  • Shiga University of Medical Science
    Shiga University of Medical ScienceClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2025
  • CA State Medical License
    CA State Medical License 2021 - 2025
  • MI State Medical License
    MI State Medical License 2010 - 2017
  • WI State Medical License
    WI State Medical License 2007 - 2011
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • The Research Project Grant (R01CA272827) Co-PI NIH/NCI, 2022
  • Translational Research Award METAvivor, 2021
  • The Research Project Grant (R01CA255240) PI NCI, 2021
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • USC Team IDs Biomarker for NSCLC Response to Chemoimmunotherapy
    USC Team IDs Biomarker for NSCLC Response to ChemoimmunotherapyMay 17th, 2023
  • USC Research Identifies Biomarker That May Predict Treatment Response to Chemoimmunotherapy
    USC Research Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
  • Study Identifies Biomarker That May Predict Treatment Response to Chemoimmunotherapy
    Study Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
  • Join now to see all

Grant Support

  • Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayNCI2022–2027
  • In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors.National Cancer Institute (NCI)2021–2026
  • Translational Research AwardMETAvivor2022–2024
  • Technology Impact AwardCancer Research Institute2019–2021
  • Peripheral Blood T-cell Dynamic Biomarkers to Identify Responders and Nonresponders in Immune Checkpoint-based Therapy for Lung CancerDOD Lung Cancer Research Program for the Office of the Congressionally Directed Medical Research Programs (CDMRP)2019–2021
  • Blood-based T-cell Biomarkers for Prediction of Treatment Response and Early Diagnosis of Immune-related Adverse Events to Immune Checkpoint InhibitorsUniversity at Buffalo Clinical and Translational Science Institute (CTSI) Translational Pilot Studies Program2019–2020
  • Adoptive Cell Therapy with Rejuvenated Antigen-specific T cellsNational Cancer Institute (NCI)2015–2020
  • Pluripotent Stem Cell-derived Genome-edited Sarcoma-targeted T cells for ImmunotherapySarcoma Foundation of America2017–2018
  • Melanoma-Targeted T cells from Pluripotent Stem Cells for ImmunotherapyMelanoma Research Alliance2015–2018
  • Induced Pluripotent Stem Cells to Generate Patient- and Tumor-Specific T cells.American College of Surgeons2014–2016
  • Induced Pluripotent Stem Cells to Generate Patient- and Tumor-Specific T cellsCentral Surgical Association2013–2014

Committees

  • Leader, USC Translational and Clinical Sciences (TACS) program 2021 - Present
  • Member, Society for Immunotherapy of Cancer (SITC) Surgery Committee 2020 - 2022
  • Member, Biostatistics & Statistical Genomics Shared Resource Advisory Committee 2018 - 2021
  • Member, IRB 2016 - 2021
  • Member, RPCI-CCSG Tumor Immunology & Immunotherapy Program 2015 - 2021
  • Core member, University of Michigan Comprehensive Cancer Center 2011 - 2015
  • Member, Cancer Committee, Ann Arbor Veterans Affairs Hospital 2011 - 2015

Research History

  • Visiting ScholarCenter for iPS Research and Application, Kyoto University, Kyoto, Japan2011 - 2011
  • Clinical/Research FellowDepartment of Immunology, Roswell Park Cancer Institute2008 - 2010
  • Research FellowDivision of Surgical Oncology, Department of Surgery, University of Michigan2000 - 2003

Professional Memberships

Other Languages

  • Japanese

Hospital Affiliations

Dr. Fumito Ito, Dr. Fumito Ito, MD, Dr. F Ito